
Recognizing Subtle ILD Symptoms in Patients With Autoimmune Disease
Interstitial lung disease (ILD) can advance quietly while patients report feeling well. The panel explains why routine symptom questions fall short and how a targeted history uncovers early lung involvement.
Episodes in this series
Welcome back to another episode of Rheum Live Cure Connections. In "Recognizing Subtle ILD Symptoms in Patients With Autoimmune Disease," moderator Vivien Hsu, MD is joined by Ara Dikranian, MD and Elizabeth (Betsy) Taylor to open the series on interstitial lung disease in people living with autoimmune conditions.
Dr. Hsu introduces herself as a Rutgers faculty member since 1996 who cares for patients with scleroderma. Dr. Dikranian describes his private rheumatology practice in San Diego and his enthusiasm for the many effective therapies now available. Betsy Taylor shares that she was diagnosed with ILD 10 years ago.
Dr. Dikranian explains that ILD can range from no symptoms at all to dyspnea, fatigue, and a dry cough. He urges clinicians to keep a longitudinal view, because a patient without symptoms today may develop them later. Autoimmune diseases can affect many organs, he notes, and the lung becomes a target of immune activation followed by fibrosis. Once ILD sets in, it may progress independently of the underlying disease.
Dr. Hsu then asks how to take a history from a patient who simply says they feel great. Dr. Dikranian recalls patients who deny dyspnea but admit they mostly sit at home and rarely challenge themselves. Short appointments push clinicians to accept answers at face value, he says, while patients settle into a new normal far from treatment goals. Dr. Hsu's favorite question is what a patient does during the day, followed by whether they can climb 12 steps or walk a city block. She also asks about oxygen use and night cough, which may signal reflux or aspiration and call for sleeping elevated.
Betsy recalls running 3 miles unable to talk, yet recovering so quickly she assumed she was in great shape. Scarring was already present when she was diagnosed in 2016. Dr. Hsu concludes that knowing each patient's baseline activity is essential. Dr. Dikranian adds that symptoms are only part of the story, and objective pulmonary function testing and imaging complete the evaluation.
Our next episode, "ILD Prevalence and Risk Factors Across Autoimmune Rheumatic Diseases," turns to how often ILD occurs in rheumatoid arthritis, systemic sclerosis, myositis, and Sjögren's disease, and which patients carry the highest risk.
Related to this article








